Business Description
Lobe Sciences Ltd
NAICS : 541710
SIC : 3741
ISIN : CA53946V2066
Description
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.7 | |||||
Equity-to-Asset | 0.06 | |||||
Debt-to-Equity | 1.04 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 54.2 | |||||
3-Year EPS without NRI Growth Rate | 36.5 | |||||
3-Year FCF Growth Rate | 48.2 | |||||
3-Year Book Growth Rate | -9.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.25 | |||||
9-Day RSI | 64.45 | |||||
14-Day RSI | 56.84 | |||||
3-1 Month Momentum % | 48.15 | |||||
6-1 Month Momentum % | 100 | |||||
12-1 Month Momentum % | 220 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.75 | |||||
Cash Ratio | 1.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -90 | |||||
Shareholder Yield % | 3.78 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -112.07 | |||||
ROIC % | -1167.01 | |||||
3-Year ROIIC % | 10.47 | |||||
ROCE % | -232.52 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -4.59 | |||||
EV-to-EBITDA | -4.59 | |||||
EV-to-FCF | -8.87 | |||||
Earnings Yield (Greenblatt) % | -21.79 | |||||
FCF Yield % | -10.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LOBEF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lobe Sciences Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.026 | ||
| Beta | 0.6771 | ||
| 3-Year Sharpe Ratio | 0.79 | ||
| 3-Year Sortino Ratio | 1.79 | ||
| Volatility % | 85.63 | ||
| 14-Day RSI | 56.84 | ||
| 14-Day ATR ($) | 0.013309 | ||
| 20-Day SMA ($) | 0.070081 | ||
| 12-1 Month Momentum % | 220 | ||
| 52-Week Range ($) | 0.0207 - 0.10855 | ||
| Shares Outstanding (Mil) | 308.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lobe Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lobe Sciences Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-01-06 | In 182 days | ||
| Annual report for 2026 | 2026-12-29 | In 174 days | ||
| General meeting for 2026 | 2026-07-30 11:00 | In 23 days | ||
| Third quarter earnings results for 2026 | 2026-07-30 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-04-29 | 0.08 (-5.04%) | ||
| First quarter earnings results for 2026 | 2026-01-29 | 0.04 (-16.99%) | ||
| Fourth quarter earnings results for 2025 | 2026-01-06 | 0.04 (-7.89%) | ||
| Annual report for 2025 | 2025-12-29 | 0.03 (+6.43%) | ||
| Third quarter earnings results for 2025 | 2025-07-30 | 0.04 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-04-28 | 0.02 (-16.67%) |
Show
Entries
Lobe Sciences Ltd Frequently Asked Questions
What is Lobe Sciences Ltd(LOBEF)'s stock price today?
The current price of LOBEF is $0.09. The 52 week high of LOBEF is $0.11 and 52 week low is $0.02.
When is next earnings date of Lobe Sciences Ltd(LOBEF)?
The next earnings date of Lobe Sciences Ltd(LOBEF) is 2026-07-30 Est..
Does Lobe Sciences Ltd(LOBEF) pay dividends? If so, how much?
Lobe Sciences Ltd(LOBEF) does not pay dividend.
Guru Commentaries on OTCPK:LOBEF
No articles.
Press Release
Articles on Lobe Sciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers